Further CEO Share Purchase
Renalytix plc announced that its Chief Executive Officer, James McCullough, purchased an additional 750 American Depositary Shares (ADS) on February 12, 2026, at an average price of $3.15 per ADS, for a total transaction value of $2,362.50. Following this purchase, Mr. McCullough now holds an interest in 3,430,096 ordinary shares, representing 0.78% of the company's issued share capital. This transaction indicates continued confidence from the CEO in the company's prospects.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces that on 12 February 2026 James McCullough, Chief Executive Officer, bought a further 750 American Depositary Shares (ADS) at an average price of US$3.15 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.
Following these purchases, James McCullough is interested in 3,430,096 Ordinary Shares1 representing 0.78% of the issued share capital of the Company.
| a) | Name | James McCullough |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive O fficer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | American Depository Shares (ADS) which consist of 50 Ordinary Shares at £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| $3.13 | 250 | |
| $3.16 | 500 | |
| d) | Aggregated information | |
| - Aggregated volume | 750 | |
| - Price | $2,362.50 | |
| e) | Date of the transaction | 12 February 2026 |
| f) | Place of the transaction | OTC New York |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.